OPPM
BMRN icon

Opus Point Partners Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Opus Point Partners Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$654K Buy
9,700
+300
+3% +$23.1K 1.18% 19
2019
Q2 		$805K Buy
9,400
+301
+3% +$25.7K 1.19% 20
2019
Q1 		$808K Sell
9,099
-599
-6% -$55.5K 1.1% 20
2018
Q4 		$826K Sell
9,698
-156
-2% -$14.8K 1.82% 15
2018
Q3 		$956K Sell
9,854
-482
-5% -$48.1K 2.28% 19
2018
Q2 		$974K Sell
10,336
-320
-3% -$28K 2.11% 20
2018
Q1 		$864K Sell
10,656
-6,462
-38% -$555K 1.69% 20
2017
Q4 		$1.53M Sell
17,118
-2,808
-14% -$244K 1.32% 27
2017
Q3 		$1.85M Buy
19,926
+3,164
+19% +$280K 1.66% 27
2017
Q2 		$1.52M Sell
16,762
-16,149
-49% -$1.47M 1.39% 29
2017
Q1 		$2.89M Buy
32,911
+1,332
+4% +$119K 2.14% 24
2016
Q4 		$2.62M Buy
31,579
+940
+3% +$80.8K 2.08% 22
2016
Q3 		$2.83M Buy
30,639
+1,724
+6% +$162K 1.59% 23
2016
Q2 		$2.25M Sell
28,915
-19,345
-40% -$1.64M 2.17% 21
2016
Q1 		$3.98M Buy
48,260
+4,390
+10% +$357K 3.08% 7
2015
Q4 		$4.6M Buy
43,870
+1,858
+4% +$194K 3.04% 15
2015
Q3 		$4.42M Buy
42,012
+6,113
+17% +$817K 2.44% 14
2015
Q2 		$4.91M Buy
35,899
+3,354
+10% +$416K 3.89% 3
2015
Q1 		$4.06M Sell
32,545
-11,186
-26% -$1.19M 3.4% 4
2014
Q4 		$3.95M Buy
+43,731
New +$3.64M 3.91% 3

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Opus Point Partners Management's BMRN Position: Q3 2019 in Review

Opus Point Partners Management increased its BioMarin Pharmaceuticals (BMRN) stake by 3.2% in Q3 2019, buying an estimated $23.1K and bringing the position to 9,700 shares worth $654K. The position accounts for 1.18% of the portfolio, ranked #19.

Opus Point Partners Management first reported a position in BMRN in Q4 2014 and has held it in 20 quarters since. The position peaked at $4.91M in Q2 2015. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Opus Point Partners Management held 9,700 shares of BioMarin Pharmaceuticals worth $654K as of Q3 2019.
  • Opus Point Partners Management bought 300 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $23.1K.
  • BioMarin Pharmaceuticals made up 1.18% of Opus Point Partners Management's portfolio in Q3 2019, its #19 holding.
  • Opus Point Partners Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Opus Point Partners Management's BioMarin Pharmaceuticals position peaked at $4.91M in Q2 2015.
  • 437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.